The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Daiichi Sankyo's quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults with acute myeloid leukaemia (AML). Each year in the UK around 3,100 people are diagnosed with AML. Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access, said: “Our […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!